For years, medical robotics has been synonymous with high-cost, high-precision interventions—think large surgical robots in complex operating rooms. But a new generation of robotics companies is upending that paradigm by targeting more routine, high-volume procedures that strain provider bandwidth and expose systemic inefficiencies.

At LSI USA ’25, a panel of operator-led companies took the stage to discuss how their technologies are addressing two of the biggest challenges in healthcare: provider scarcity and rising costs. While traditional robotics may have focused on elite surgical tasks, the next wave is all about scalable, task-specific solutions that work within real-world clinical and economic constraints.

From Specialized to Scalable: Redefining the Role of Medical Robotics

Rather than targeting a handful of high-reimbursement procedures, these companies are applying robotics to common clinical workflows—vascular access, phlebotomy, biopsies—that collectively account for hundreds of millions of procedures annually. The goal isn’t just precision. It’s consistency, throughput, and accessibility.

One company has developed a lightweight, handheld robotic system that interfaces with imaging tools to guide needle-based procedures. Another has built a fully autonomous phlebotomy console that performs everything from vein detection to sample labeling and vial inversion—entirely without human intervention. These aren’t surgical robots; they’re task-focused machines designed for deployment at scale.

This shift reflects a broader understanding: solving healthcare’s biggest pain points often means moving away from the OR and into high-volume areas where inefficiencies are compounded. A single blood draw may not carry a high per-procedure value, but billions of blood draws annually create massive aggregate opportunity. That’s where automation begins to make real economic sense.

Rethinking Value in Medical Robotics

The traditional medical robotics business model often hinges on one or two reimbursed procedures and a long, expensive sales cycle. These new approaches challenge that playbook.

Rather than design around a single CPT code, these companies are building systems that can serve multiple applications and workflows across provider types. They’re shifting away from specialist-only tools and toward technologies that can be used by generalists—or even by patients themselves.

It’s not just about simplifying the technology; it’s about aligning robotic architecture with the constraints and incentives of the real world. That means smaller, more affordable systems. Faster deployments. Plug-and-play integration into existing care environments. And, importantly, a business model that doesn’t rely on traditional medtech reimbursement structures.

This kind of thinking is especially critical when considering how to make these systems commercially viable. Early-stage deployment goals might involve placing 10 or 20 units—not hundreds—making supply chain scalability and per-unit economics essential from day one.

Talent, Data, and the AI Equation

The conversation also turned toward AI and autonomy—now central to how modern medical robotics are designed and experienced. But while consumer robotics can iterate quickly with abundant data, healthcare robotics face a unique barrier: clinical data scarcity.

Access to multimodal datasets—including imaging, vitals, and unstructured EMR notes—remains a major bottleneck. This challenge has real implications for how robotic systems are trained, tested, and deployed. Even the most advanced AI models won’t succeed without the right inputs—and in healthcare, getting those inputs is rarely straightforward.

Attracting and retaining top talent in AI and robotics is another pain point, particularly as high-valuation companies in adjacent industries compete for the same engineers and scientists. To succeed, medtech startups need more than a mission—they need a compelling technical challenge, a clear path to impact, and a product that can scale well beyond the pilot phase.

The Economics of Building Big

For companies raising capital in the robotics space, the stakes are high. With funding rounds often topping $50 million—or even $100 million—these businesses can’t rely on traditional medtech exits. A $300 million acquisition won’t move the needle for most of their investors.

Instead, these founders are aiming to build durable, standalone companies with public-market potential. That means aligning with investors who understand the vision, the capital intensity, and the longer-term path to scale. Importantly, it also means funding multiple milestones at once—development, regulatory, and early commercial—not just one step at a time.

But that path is only viable if there’s a healthy ecosystem of acquirers and growth-stage capital. While there’s renewed momentum in smaller M&A deals, consolidation among strategics creates challenges. Fewer buyers mean more technologies risk stalling between regulatory approval and full market access. The industry needs more acquirers—and more companies that can themselves become acquirers—to keep innovation alive.

Cross-Sector Lessons and Future Impact

Many of the most effective strategies in today’s medical robotics space are drawn not from the hospital but from logistics, manufacturing, and consumer tech. That’s not a coincidence. Robots in warehousing environments are built for speed, scale, and repeatability. Applying that mindset to healthcare—without compromising safety—can unlock an entirely new category of solutions.

There’s also a shift underway in how stakeholders interact with robotics. These aren’t tools for a single specialist in a high-end OR—they’re systems that patients, nurses, and even low-acuity providers must feel comfortable using. Design, user experience, and trust-building are all just as important as functionality.

Ultimately, medical robotics will succeed not by dazzling in complexity but by delivering consistent, scalable value across a wide range of care settings.

The Future of Medical Robotics Is Purpose-Built

This panel made one thing clear: the next chapter of medical robotics isn’t about adding more bells and whistles to existing platforms. It’s about building smarter, leaner systems that solve real-world problems at scale.

As healthcare systems face mounting pressure from staffing shortages, cost inflation, and demand for access, robotics offers a rare combination of reliability and repeatability. But only if innovators are willing to rethink the business models, workflows, and value assumptions that have long defined the category.

From phlebotomy to biopsies and beyond, the future of medical robotics belongs to technologies that blend automation, affordability, and patient-centric design. And that future is already taking shape.

Want more insights like this? Join us in London this September for our next medical technology conference.